Why Oppenheimer is Bullish on Tiny Biotech Aprea Therapeutics
Oppenheimer backs Aprea with $5 target. Its cancer drug shows early promise, and low valuation offers big upside potential.
NOTRELOAD AI
Angelini Pharma Buys US Catalyst for $4.1 Billion in State-Backed Deal
Angelini is set to buy US-based Catalyst for $31.50 per share in a state-backed deal, expanding into rare neurological diseases and entering the US market.
Rackspace and AMD Team Up to Build Secure AI Cloud for Big Companies
Rackspace jumped after partnering with AMD to build secure AI cloud for banks and hospitals using AMD + Nvidia chips for AI workloads.
Dystrophin Miss Sends Entrada Shares Tumbling Despite Functional Win
Entrada DMD drug was safe and helped movement a bit, but low muscle protein results disappointed investors, stock -60%.
Morgan Stanley, RBC, and Others Lift Arm Targets as Agentic AI Optimism Outweighs Near-Term Concerns
ARM beat earnings and saw strong demand for AI chips, but shares fell on smartphone worries amid supply concerns. Analysts still raised price targets.
Peloton Surprises with Profit and Raises Full-Year Outlook
Peloton Q3 shows profit, higher revenue, strong cash flow, less debt, but subscribers still falling; outlook improved.